Vaccinex, Inc. - VCNX STOCK NEWS

Vaccinex Inc. (Nasdaq: VCNX) is showcasing insights on pepinemab's action mechanism against neurodegenerative diseases at the AAIC Advancements: Immunity conference on March 24, 2023. COO Elizabeth Evans will discuss findings on semaphorin 4D's (SEMA4D) role in Huntington’s Disease and Alzheimer’s Disease.

The ongoing clinical trial, SIGNAL AD, is pivotal, with topline data expected in mid-2024. The presentation emphasizes targeting neuroinflammation as a novel treatment approach. Vaccinex's innovative strategy aims to inhibit SEMA4D to combat chronic neurodegenerative conditions.

Vaccinex, Inc. (Nasdaq: VCNX) announced a Phase Ib/2 study evaluating pepinemab in combination with avelumab for patients with metastatic pancreatic adenocarcinoma (PDAC). The trial, conducted at the University of Rochester, aims to assess safety and efficacy in overcoming the immunosuppressive tumor microenvironment. Sponsored by Vaccinex and supported by the Gateway Discovery Award, the study is critical given PDAC's low 5-year survival rate of 5-10%. It focuses on enhancing immune response by reversing immunosuppression within the tumor microenvironment. Pepinemab's favorable safety profile in earlier studies could offer new treatment hope for PDAC patients.

Vaccinex, Inc. (Nasdaq: VCNX) has enrolled 36 subjects in the Phase 1b/2 KEYNOTE-B84 study to evaluate pepinemab combined with Merck's KEYTRUDA for treating recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). An interim analysis is planned upon completion of tumor assessments, with results expected in mid-2023. The study aims to determine the safety and efficacy of this combination therapy, particularly in patients with low PD-L1 expression. Pepinemab is noted for its potential to enhance immune responses while maintaining safety profiles associated with KEYTRUDA.

Vaccinex, Inc. announced that its licensee, Surface Oncology, has initiated a Phase 1/2 clinical trial for SRF114, an antibody discovered using Vaccinex’s ActivMAb® platform. This is a significant milestone as it validates the ActivMAb® technology. SRF114 targets CCR8 to selectively deplete immuno-suppressive tumor T regulatory cells, potentially positioning it as a best-in-class therapy for advanced solid tumors. Under the licensing agreement, Vaccinex stands to benefit from milestone payments and royalties on sales.

Vaccinex, Inc. (Nasdaq: VCNX) has closed a private placement of 7,142,496 shares at $0.5293 per share, raising approximately $3.8 million. The deal, completed on November 23, 2022, involved major investors from within the company's leadership team, who collectively bought $2.9 million in shares. The funds will support ongoing development and clinical trials of pepinemab, its lead drug candidate, targeting cancer and neurodegenerative diseases. A registration rights agreement has been established, allowing for the resale of shares under a future registration statement.

Vaccinex, a clinical-stage biotechnology firm, reported progress on its clinical programs for pepinemab, a SEMA4D inhibitor. The Phase 1b/2 KEYNOTE B84 study with KEYTRUDA® in head and neck cancer shows promising initial responses, with confirmed complete responses observed in patients with low PD-L1 expression. Financially, Vaccinex reported a net loss of $4.8 million for Q3 2022, a slight decrease from the previous year. The company aims to meet with the FDA regarding the use of HD-CAB as a potential surrogate endpoint to accelerate the approval process for Huntington's Disease treatment.

Vaccinex Inc. (Nasdaq: VCNX) announced promising findings regarding its drug pepinemab at the SITC 37th Annual Meeting. Two studies highlighted the drug's potential when combined with immunotherapy for treating Stage III melanoma and HER2+ metastatic breast cancer. Results showed a remarkable 100% recurrence-free rate after 24 months for patients treated with a triple combination of pepinemab, nivolumab, and ipilimumab. The findings underline the importance of biomarkers in determining treatment efficacy and the drug's capacity to enhance immune responses. Vaccinex is also pursuing further studies, including a Phase 1b/2 trial.

Vaccinex, a clinical-stage biotech focused on cancer and neurodegenerative diseases, reported promising initial responses in the Phase 1b/2 KEYNOTE B84 study of pepinemab combined with KEYTRUDA® for advanced head and neck cancer. They also published results from the Phase 2 SIGNAL study in Huntington's Disease in Nature Medicine, showing potential cognitive benefits despite not meeting primary endpoints. Financially, Vaccinex reported $11.4 million in cash and equivalents, with a net loss of $5.4 million for Q2 2022, an improvement from $6.0 million in Q2 2021.

Vaccinex, Inc. (VCNX) has released findings from its Phase 2 SIGNAL trial, showcasing the potential of its SEMA4D-blocking antibody, pepinemab, to address cognitive decline in Huntington’s Disease (HD). Although the primary efficacy endpoints were not met, significant reductions in brain atrophy and preservation of metabolic activity were reported. Furthermore, the article published in Nature Medicine highlights cognitive improvements, especially in patients with early symptoms. The company is initiating a Phase 1b/2a study for Alzheimer's Disease, suggesting broader implications for neurodegenerative treatments.